Synlogic, Inc. logo

Synlogic, Inc.

Synlogic operates and develops proprietary microbial engineering platform for the development of therapeutic microbes. Synlogic (NASDAQ CM: SYBX) is a microbiome company, developing proprietary living Synthetic BioticTM medicines for the treatment of inborn errors of metabolism (IEM), inflammation, metabolism, oncology and CNS.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”SYBX” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.synlogictx.com
Founded2013
Disease Focus
Development Stage
STOCK CODENASDAQ: SYBX
Address
301 Binney St.; #402, MA 02142
Cambridge
United States
Email
Contact Number
+1 617-401-9975

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/synlogic-therapeutics” connections=”true” suffix=””]

Synlogic applies synthetic biology to non-pathogenic bacteria (E.coli Nissle) to develop _Synthetic Biotic MedicinesÓ capable of manipulating multiple pathways relevant for the treatment of cancer and autoimmunity. Its synthetic biology platform allows to design bacterial strains capable of executing metabolic conversions (production or consumption of metabolites), secretion of proteins (chemokines, cytokines, enzymes) and secretion or display of single -chain F(scFv) molecules (to interfere with ligand -receptor interactions). In cancer this effectively trigger innate and adaptive immune responses by intratumoral expression of a variety of effectors, such as STING agonists, TNF? and IFN?, and reverse immunosuppression by consumption of suppressive metabolites. These strains show robust anti-tumor activity in B16F10 and CT26 syngeneic mouse models, as single agents or in combination with checkpoint inhibitors.

Synlogic uptill May 2017, raised $116.4 Mn in four funding rounds. In 2017, Synlogic raised $42 Mn in Series C funding from Aju IB Investment, Ally Bridge Group, Arctic Aurora LifeScience, CLI Ventures, Perceptive Advisors, Rock Springs Capital, and other undisclosed new investors. Existing investors, Atlas Venture, Deerfield, New Enterprise Associates and OrbiMed also participated in the financing. Earlier, in 2016, it raised $40Mn in series B funding and between 2014-16, Synlogic received an amount of $34.4Mn in Series A funding. The lead investors being OriMed Healthcar, Atlas Venture.